Intervention Group | Control Group | |
---|---|---|
Recruitment visit (V 0) | Selection criteria | |
Consecutive selection | Request on informed consent | |
PRIME MD Questionnaire | ||
Variables: | ||
· SF-12 Questionnaire on life quality | ||
· Descriptive variables: sex, cultural level, age, months with symptoms, time on antidepressants consumption, requested tests y specialized derivations to | ||
Training of professionals involved | Training in management of PRIME-MD survey. Review of Standards of Good Clinical Practice | |
Training in cognitive-behavioral (Only intervention Group) | ||
Baseline visit (V1) | Variables: | |
· SF-12 Questionnaire | ||
· Prescribed medicine | ||
· Requested tests | ||
· Derivations to secondary level | ||
· Days of sickness absence | ||
· Assessment of compliance with the standards of good clinical practice | ||
· Questionnaire on global clinical impression; both, the doctor and the patient | ||
Intervention | There will be a weekly group session for 4 weeks (Only intervention Group) | |
Routine clinical practice | ||
3-months post Intervention visit (V2) | Variables: | |
· SF-12 Questionnaire | ||
· Prescribed medicine | ||
· Requested tests | ||
· Derivations to secondary level | ||
· Days of sickness absence | ||
· Assessment of compliance with the standards of good clinical practice | ||
· Questionnaire on global clinical impression; both, the doctor and the patient | ||
· Assessment by the nurse subject participation. | ||
· Assessment of cognitive- behavioral module by subject (Only intervention Group) | ||
6-months post Intervention visit (V3) 12-months post Intervention visit (V4) | Variables: | |
· SF-12 Questionnaire | ||
· Prescribed medicine | ||
· Requested tests | ||
· Derivations to secondary level | ||
· Days of sickness absence | ||
· Assessment of compliance with the standards of good clinical practice | ||
· Questionnaire on global clinical impression; both, the doctor and the patient | ||
· Assessment of cognitive- behavioral module by subject (Only intervention Group) |